Navigation Links
InterMune to Release Third Quarter Financial Results on November 3
Date:10/27/2011

BRISBANE, Calif., Oct. 27, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2011 financial results at the close of the U.S. markets on Thursday, November 3, 2011.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 22885421.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 22885421.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
2. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
3. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
4. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune Reports Third Quarter 2010 Financial Results
7. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
8. InterMune to Release Second Quarter Financial Results on July 27
9. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
10. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
11. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... 50 years ago today, the Monterey Pop Festival opened its ... San Francisco "Summer of Love."  To celebrate the anniversary, Northern ... strategic market research portals that it will begin delivering to ... Light,s "Summer of Love (For Our Customers)."  ... Northern ...
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/13/2017)... WARSAW, Ind. , June 13, 2017 Zimmer ... in musculoskeletal healthcare, today announced that the U.S. Food and ... Letter dated June 3, 2015 relating to its ... "The successful clearance of ... China manufacturing facility is a measure of the ...
Breaking Medicine Technology:
(Date:6/20/2017)... York, NY (PRWEB) , ... June 20, 2017 , ... ... today their continued expansion and success in the clinical trials market. Similar to its ... a track record in the clinical trials marketplace by proving the value of eVisits ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), a ... new products designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric is ... care stretch twill. , With trendy looks hitting the medical community, UA Flex is ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... would like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory ... insight and expertise in healthcare will provide invaluable direction for the company,” says ...
(Date:6/19/2017)... ... ... The joyful summer wedding season is upon us, but it’s also mosquito ... wet spring have created ideal conditions for mosquitoes and ticks poised to swoop in ... when a bride and groom are saying their "I do's,” observes Manuel Castro, co-founder ...
Breaking Medicine News(10 mins):